` URT (Urteste SA) vs WIG20 Comparison - Alpha Spread

U
URT
vs
W
WIG20

Over the past 12 months, URT has underperformed WIG20, delivering a return of -36% compared to the WIG20's +33% growth.

Stocks Performance
URT vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
URT vs WIG20

Performance Gap Between URT and WIG20
HIDDEN
Show

Performance By Year
URT vs WIG20

Loading
URT
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Urteste SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Urteste SA
Glance View

Market Cap
80.7m PLN
Industry
Biotechnology

Urteste SA specializes in the development of technology that allows the detection of cancers at early stages of their development. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-10-27. The firm operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The firm offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.

URT Intrinsic Value
HIDDEN
Show
Back to Top